What is Primary Hepatoma (Hepatocellular Carcinoma)?
Primary hepatoma, also known as hepatocellular carcinoma (HCC), is a malignant epithelial tumor that originates from hepatocytes (liver cells) and represents the most common primary liver cancer in adults, accounting for approximately 75-85% of all primary liver malignancies 1, 2, 3.
Epidemiology and Global Burden
HCC ranks as the sixth most common cancer worldwide and the third leading cause of cancer-related death globally 1, 4. The incidence varies dramatically by geography:
- Low incidence: Northern Europe and North America (2-5 per 100,000 per year) 5
- High incidence: Sub-Saharan Africa and Far East Asia, correlating with endemic hepatitis B and C virus infections 6
- Rising trend: The United States has seen the fastest-growing cancer incidence rate for HCC, with steadily increasing mortality rates from 1975-2006 3
Pathophysiology and Cell of Origin
HCC is an adenocarcinoma where tumor cells morphologically resemble normal hepatocytes 2. The cell of origin remains debated—it may arise from either:
- Mature hepatocytes undergoing malignant transformation
- Liver stem/progenitor cells (suggested by biliary-type cytokeratin CK7/CK19 positivity, which carries a poor prognosis) 1
The tumor develops through a genetic progression model similar to other cancers, evolving from dysplastic lesions to frank malignancy 1. Stromal invasion into portal tracts or fibrous septa definitively distinguishes HCC from premalignant dysplastic nodules 2.
Risk Factors and Underlying Liver Disease
HCC is strongly associated with cirrhosis in 80-90% of cases 5, 7, 6. A liver with advanced fibrosis—regardless of etiology—provides the "ideal soil" for HCC development 1.
Major Risk Factors:
Viral hepatitis:
- Chronic hepatitis B virus (HBV) infection
- Chronic hepatitis C virus (HCV) infection
- These create a 2-5% annual incidence of HCC in cirrhotic patients 6
Metabolic and toxic factors:
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD
- Alcohol-related liver disease
- These are increasingly prominent in Western populations as antiviral therapies reduce viral hepatitis burden 4
Other factors:
- Iron overload (hemochromatosis)
- Aflatoxin B1 exposure (particularly in Africa with concurrent HBV) 2
- Male gender, advanced age, obesity, type 2 diabetes 1, 6
Important Caveat:
Less than 10% of HCC cases occur in non-cirrhotic, normal livers 1. These cases may arise from specific adenoma subtypes 1.
Histological Variants
Primary HCC includes several variants that should be recognized 5:
- Classic HCC (most common)
- Fibrolamellar carcinoma: Occurs in young patients without cirrhosis or risk factors; has significantly better prognosis and slower growth; typically excluded from therapeutic trials 1
- Clear cell carcinoma
- Giant cell carcinoma
- Steatohepatitic HCC: Associated with NAFLD/NASH background 8
Clinical Significance
HCC is unique in oncology because it is largely preventable through:
- Universal hepatitis B vaccination at birth 2
- Antiviral eradication of HBV and HCV
- Control of alcohol consumption and metabolic risk factors 1
However, despite being preventable and potentially curable when detected early, survival remains poor: only 30% of patients survive 1 year, and only 12.5% survive 5 years overall 7. When diagnosed at an early stage, 1-year survival improves to 80% 7.
Diagnostic Approach
HCC diagnosis requires histopathological confirmation in most cases, obtained via:
- Ultrasound or CT-guided biopsy
- Laparoscopy
- Open surgery 5
Exception: Cirrhotic patients with alpha-fetoprotein (AFP) >500 ng/mL can be diagnosed without biopsy 5.
Non-invasive diagnosis is possible in cirrhotic patients using state-of-the-art imaging (multidetector CT or dynamic contrast-enhanced MRI) showing the characteristic vascular pattern: arterial phase hypervascularization with venous/delayed phase washout 2.
Management Context
HCC management is complicated by the "one patient with two diseases" phenomenon—the cancer itself plus underlying cirrhosis with hepatic dysfunction 3. This dual pathology:
- Limits treatment options
- Complicates clinical trial eligibility
- Requires careful assessment of both tumor burden and liver function (Child-Pugh classification) 5
Over 70% of patients present with advanced disease ineligible for curative therapies (resection, transplantation, locoregional ablation), representing a major unmet medical need 3.